Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) to a strong-buy rating in a research note published on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for Pliant Therapeutics’ Q3 2024 earnings at ($1.00) EPS, Q4 2024 earnings at ($0.98) EPS, FY2024 earnings at ($3.69) EPS, Q1 2025 earnings at ($0.97) EPS, […]